Saltar al contenido
Merck

Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats.

Die Pharmazie (2015-05-23)
R Sawamura, M Kazui, A Kurihara, T Izumi
RESUMEN

This study was conducted to evaluate the pharmacokinetics of loxoprofen (LX) and its active metabolite (trans-OH form) after a single dermal application of LX gel (LX-G) to rats. In the skin at the treated site, generation of the trans-OH form was detected and both LX and the trans-OH form remained at high concentrations for 24 h after dermal application. Furthermore, both LX and the trans-OH form also remained in the skeletal muscle over 24 h after the single dermal application, while they eliminated rapidly after the single oral administration. The area under the curve up to the last measurable point (AUC(0-t)) for plasma concentrations of LX or the trans-OH form after dermal application of LX-G was less than 11% of that after oral administration of LX. In addition, C(max) and AUC(0-t) increased in a saturable manner while increasing the dose. Overall, these results demonstrated that the trans-OH form was generated at the treated site with the process of dermal absorption of LX and it remained at the target site for a long period with low systemic exposure compared to oral administration.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Propylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Propylparaben, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Phenobarbital
Sigma-Aldrich
Propyl 4-hydroxybenzoate, ≥99%
Supelco
Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Propyl 4-hydroxybenzoate, BioXtra
Propyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Propyl 4-hydroxybenzoate, tested according to Ph. Eur.